LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Savara Inc

Savara Inc

Затворен

СекторЗдравеопазване

5.6 -3.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.5600000000000005

Максимум

5.93

Ключови измерители
By Trading Economics
Приходи	840K -30M
EPS	-0.14
Служители	59
EBITDA	841K -29M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+75.81% upside

Дивиденти
By Dow Jones
Следващи печалби	26.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	259M 1.1B
Предишно отваряне	9.05
Предишно затваряне	5.6

Настроения в новините

By Acuity

16%

84%

25 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

2.76 / 2.84 Подкрепа & съпротива

Savara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.02.2026 г., 16:32 ч. UTC

Печалби

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13.02.2026 г., 21:57 ч. UTC

Печалби

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:20 ч. UTC

Печалби

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13.02.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Dollar Pares Down Early Losses -- Market Talk

13.02.2026 г., 20:39 ч. UTC

Пазарно говорене

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13.02.2026 г., 20:28 ч. UTC

Пазарно говорене

Oil Settles Week Lower -- Market Talk

13.02.2026 г., 19:51 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:29 ч. UTC

Печалби

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13.02.2026 г., 18:18 ч. UTC

Придобивния, сливания и поглъщания

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13.02.2026 г., 17:52 ч. UTC

Печалби

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13.02.2026 г., 17:16 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13.02.2026 г., 16:59 ч. UTC

Печалби

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13.02.2026 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13.02.2026 г., 16:11 ч. UTC

Печалби

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13.02.2026 г., 16:07 ч. UTC

Пазарно говорене

Hungarian Forint Could Rise Further -- Market Talk

13.02.2026 г., 15:54 ч. UTC

Печалби

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13.02.2026 г., 15:26 ч. UTC

Пазарно говорене

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13.02.2026 г., 15:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13.02.2026 г., 15:00 ч. UTC

Печалби

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13.02.2026 г., 14:50 ч. UTC

Пазарно говорене

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13.02.2026 г., 14:44 ч. UTC

Печалби

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13.02.2026 г., 14:22 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

13.02.2026 г., 14:21 ч. UTC

Пазарно говорене

Печалби

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13.02.2026 г., 14:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Move Lower -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Savara Inc Прогноза

Ценова цел

By TipRanks

75.81% нагоре

12-месечна прогноза

Среден 10.25 USD 75.81%

Висок 11 USD

Нисък 9 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Savara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Savara Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.76 / 2.84Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Настроение

By Acuity

25 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.